| Name: | Description: | Size: | Format: | |
|---|---|---|---|---|
| 2 MB | Adobe PDF |
Advisor(s)
Abstract(s)
Prostate cancer is one of the most common non-cutaneous malignancies among men worldwide. Epigenetic aberrations, including changes in DNA methylation patterns and/or histone modifications, are key drivers of prostate carcinogenesis. These epigenetic defects might be due to deregulated function and/or expression of the epigenetic machinery, affecting the expression of several important genes. Remarkably, epigenetic modifications are reversible and numerous compounds that target the epigenetic enzymes and regulatory proteins were reported to be effective in cancer growth control. In fact, some of these drugs are already being tested in clinical trials. This review discusses the most important epigenetic alterations in prostate cancer, highlighting the role of epigenetic modulating compounds in pre-clinical and clinical trials as potential therapeutic agents for prostate cancer management.
Description
Keywords
Prostate cancer DNMTi Histone modulators
Citation
Graça, I., Pereira-Silva, E., Henrique, R., Packham, G., Crabb, S. J., & Jerónimo, C. (2016). Epigenetic modulators as therapeutic targets in prostate cancer. Clinical Epigenetics, 8(1), 98. https://doi.org/10.1186/s13148-016-0264-8
Publisher
BioMed Central